Clinical trials: Liposarcoma, Dedifferentiated
Liposarcoma, Leiomyosarcoma
Efficacy Study on Trabectedin in Retroperitoneal Leiomyosarcoma and Well Differentiated/Dedifferentiated Liposarcoma
This is an Italian, multicentre, single arm, phase II study, with an intra-patient comparison end point. This study aims at confirming the activity of the drug trabectedin as second/further line treatment in retroperitoneal…
- Trial name
- TRAVELL (NCT02247544)
- Testing
- Trabectedin
- Where
- 21 sites in Italy
- Volunteers
- 105 people
- Sponsor
- Italian Sarcoma Group
Advanced Dedifferentiated Liposarcoma
SARC041: Study of Abemaciclib Versus Placebo in Patients With Advanced Dedifferentiated Liposarcoma
This is a Phase 3 randomized double-blind study of abemaciclib versus placebo. Patients with progression of disease will cross over to open label abemaciclib.
- Trial name
- NCT04967521
- Testing
- Abemaciclib
- Where
- 9 sites in United States
- Volunteers
- 108 people
- Sponsor
- Sarcoma Alliance for Research through Collaboration
Dedifferentiated Liposarcoma
Selinexor in Advanced Liposarcoma
This is a randomized, multicenter, double-blind, placebo-controlled, Phase 2-3 study of patients diagnosed with advanced unresectable dedifferentiated liposarcoma.
- Trial name
- SEAL (NCT02606461)
- Testing
- Selinexor
- Where
- 71 sites in United States, Belgium and 8 more
- Volunteers
- 342 people
- Sponsor
- Karyopharm Therapeutics Inc
Locally Advanced Bone Sarcoma, Locally Advanced Dedifferentiated Liposarcoma
Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Sarcoma That Cannot Be Removed by Surgery
This randomized phase II trial studies how well nivolumab with or without ipilimumab works in treating patients with sarcoma that has spread from the primary site to other parts of the body (metastatic) or cannot be removed by…
- Conditions
- Locally Advanced Bone Sarcoma, Locally Advanced Dedifferentiated Liposarcoma, Locally Advanced Gastrointestinal Stromal Tumor, Locally Advanced Soft Tissue Sarcoma
- Trial name
- NCT02500797
- Testing
- Ipilimumab, Laboratory Biomarker Analysis, Nivolumab
- Where
- 651 sites in United States
- Volunteers
- 164 people
- Sponsor
- National Cancer Institute (NCI)
Dedifferentiated Liposarcoma
Treatment of Milademetan Versus Trabectedin in Patient With Dedifferentiated Liposarcoma
Randomized, multicenter, open-label, Phase 3 registration study designed to evaluate the safety and efficacy of milademetan compared to trabectedin in patients with unresectable (i.e., where resection is deemed to cause…
- Trial name
- MANTRA (NCT04979442)
- Testing
- RAIN-32, Trabectedin
- Where
- 71 sites in United States, Austria and 13 more
- Volunteers
- 175 people
- Sponsor
- Rain Oncology Inc
Dedifferentiated Liposarcoma, Soft Tissue Sarcoma (STS)
First-line Treatment of Advanced/unresectable DDLPS
Evaluating the efficacy and safety of liposomal doxorubicin hydrochloride and apatinib in combination with camrelizumab for the first-line treatment of advanced/unresectable dedifferentiated liposarcoma
- Trial name
- NCT06694324
- Testing
- Liposomal Doxorubicin (Doxil), Apatinib, Camrelizumab
- Where
- China
- Volunteers
- 49 people
- Sponsor
- Fudan University
Uveal Melanoma, Melanoma
A Study of LN-144 or LN-145 in People With Advanced Uveal Melanoma, Undifferentiated Pleomorphic Sarcoma, Dedifferentiated Liposarcoma, or Angiosarcoma
This is an open label study evaluating lifileucel (LN-144) in patients with metastatic uveal melanoma.
- Conditions
- Uveal Melanoma, Melanoma, Metastatic Uveal Melanoma, Metastatic Melanoma
- Trial name
- NCT05607095
- Testing
- Lifileucel (LN-144/LN-145)
- Where
- 2 sites in United States
- Volunteers
- 40 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Sarcoma
Circulating " Cancer Cells / Macrophage " HYbrid Cells in Patients With Sarcoma?
Pilot, prospective, monocentric study aimed at evaluating the rate of patients with circulating "cancer cell/macrophage" hybrid cells in the peripheral blood.
- Trial name
- SAMHY SARCOME (NCT04512495)
- Testing
- Blood samples will be collected at two times :
- Where
- France
- Volunteers
- 60 people
- Sponsor
- Institut Claudius Regaud
Dedifferentiated Liposarcoma
Study Evaluating the Efficacy and Safety of IPI 504 in Patients With Advanced Dedifferentiated Liposarcoma
The primary objective of the study is to determine the safety profile and overall response rate of IPI 504 in patients with advanced dedifferentiated liposarcoma.
- Trial name
- NCT00969917
- Testing
- IPI-504
- Where
- United States
- Sponsor
- Infinity Pharmaceuticals, Inc.
Solid Tumor, Sarcoma
STC-15 as a Part of Combination Therapy With Toripalimab in Selected Advanced Cancers and as Monotherapy in Participants With Selected Sarcomas
This early phase oncology trial will be conducted at various study centers to investigate the safety, tolerability, and antitumor activity of STC-15 (a METTL3 inhibitor) in combination with toripalimab (anti- programmed cell…
- Conditions
- Solid Tumor, Sarcoma, Leiomyosarcoma, Dedifferentiated Liposarcoma
- Trial name
- NCT06975293
- Testing
- STC-15 in combination with toripalimab, STC-15 monotherapy
- Where
- 14 sites in United States
- Volunteers
- 107 people
- Sponsor
- STORM Therapeutics LTD
Liposarcomas, Dedifferentiated, Liposarcoma - Well Differentiated
A Study Assessing Efficacy & Safety of Ribociclib in Patients With Advanced Well/Dedifferentiated Liposarcoma
The purpose of this study is to determine whether ribociclib are effective and safe in the treatment of progressive well/dedifferentiated liposarcoma (WDL/DDL).
- Conditions
- Liposarcomas, Dedifferentiated, Liposarcoma - Well Differentiated, Liposarcoma; Mixed Type, Soft-Tissue Sarcoma
- Trial name
- NCT03096912
- Testing
- Ribociclib
- Where
- Israel
- Volunteers
- 30 people
- Sponsor
- Assaf-Harofeh Medical Center
Leiomyosarcoma, Malignant Peripheral Nerve Sheath Tumor
Nivolumab and BO-112 Before Surgery for the Treatment of Resectable Soft Tissue Sarcoma
This phase I trial studies the side effects of BO-112 when given together with nivolumab before surgery in treating patients with soft tissue sarcoma that can be removed by surgery (resectable).
- Conditions
- Leiomyosarcoma, Malignant Peripheral Nerve Sheath Tumor, Myxofibrosarcoma, Pleomorphic Rhabdomyosarcoma
- Trial name
- NCT04420975
- Testing
- Definitive Surgical Resection, Nanoplexed Poly I:C BO-112, Nivolumab
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Conventional Chondrosarcoma, Myxoid Liposarcoma
Sirolimus and Cyclophosphamide in Metastatic or Unresectable Myxoid Liposarcoma and Chondrosarcoma
Chondrosarcoma and liposarcoma consists of different subtypes with a wide range of patient survival. Current treatment options consist of wide surgical resection, however for patients with a local recurrence or metastatic disease…
- Conditions
- Conventional Chondrosarcoma, Myxoid Liposarcoma, Mesenchymal Chondrosarcoma, Dedifferentiated Chondrosarcoma
- Trial name
- NCT02821507
- Testing
- sirolimus and cyclophosphamide
- Where
- 7 sites in Netherlands, Spain
- Volunteers
- 70 people
- Sponsor
- Leiden University Medical Center
Dedifferentiated Liposarcoma
Ph II Cabazitaxel DD Liposarcoma
Soft tissue sarcomas (STS) are a rare group of malignant heterogenous tumors (> 50 histological subtypes, including liposarcoma, the commonest subtype of STS) with distinct genetic, pathological and clinical profiles, and varying…
- Trial name
- NCT01913652
- Testing
- Cabazitaxel
- Where
- 11 sites in Belgium, France and 2 more
- Volunteers
- 42 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Liposarcoma, Soft Tissue Sarcoma
A Phase II Study Assessing Efficacy & Safety of Ribociclib in Patients With Advanced Well/Dedifferentiated Liposarcoma
The purpose of this study is to determine whether ribociclib are effective and safe in the treatment of progressive well/dedifferentiated liposarcoma (WDL/DDL).
- Trial name
- NCT02571829
- Testing
- ribociclib
- Where
- Israel
- Volunteers
- 30 people
- Sponsor
- Hadassah Medical Organization
Sarcoma, Soft Tissue Sarcoma (STS)
A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Soft Tissue Sarcoma
A study of lifileucel (tumor-infiltrating lymphocytes) in adults with advanced soft tissue sarcoma ('SARATOGA')
- Conditions
- Sarcoma, Soft Tissue Sarcoma (STS), Advanced Soft Tissue Sarcoma, Undifferentiated Pleomorphic Sarcoma (UPS)
- Trial name
- 'SARATOGA' (NCT07741877)
- Testing
- Lifileucel
- Where
- 2 sites in United States
- Volunteers
- 80 people
- Sponsor
- Iovance Biotherapeutics, Inc.
Advanced Dedifferentiated Liposarcoma, Advanced Leiomyosarcoma
Testing the Addition of an Anti-cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (Gemcitabine) for Soft Tissue Sarcoma
This phase I/II trial tests the side effects and best dose of abemaciclib when added to gemcitabine and compares the effectiveness of that treatment to the usual treatment of gemcitabine with docetaxel for the treatment of…
- Conditions
- Advanced Dedifferentiated Liposarcoma, Advanced Leiomyosarcoma, Advanced Soft Tissue Sarcoma, Metastatic Dedifferentiated Liposarcoma
- Trial name
- NCT06498648
- Testing
- Abemaciclib, Biopsy Procedure, Biospecimen Collection
- Where
- United States
- Volunteers
- 74 people
- Sponsor
- National Cancer Institute (NCI)
Metastatic Angiosarcoma, Metastatic Dedifferentiated Liposarcoma
Oleclumab and Durvalumab for the Treatment of Recurrent, Refractory, or Metastatic Sarcoma
This phase II trial investigates how well oleclumab and durvalumab work in treating patients with sarcoma that has come back (recurrent) or does not respond to treatment (refractory) or has spread to other places in the body…
- Conditions
- Metastatic Angiosarcoma, Metastatic Dedifferentiated Liposarcoma, Metastatic Osteosarcoma, Recurrent Angiosarcoma
- Trial name
- DOSa (NCT04668300)
- Testing
- Durvalumab, Oleclumab
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- M.D. Anderson Cancer Center
Metastatic Dedifferentiated Liposarcoma, Metastatic Leiomyosarcoma
Testing Low-Dose Common Chemotherapy (Liposomal Doxorubicin) in Combination With an Anti-Cancer Drug, Peposertib, in Advanced Sarcoma
This phase I trial tests the safety, side effects, and best dose of combination therapy with liposomal doxorubicin and peposertib in treating patients with sarcoma that has spread from where it first started, to other places in…
- Conditions
- Metastatic Dedifferentiated Liposarcoma, Metastatic Leiomyosarcoma, Metastatic Myxofibrosarcoma, Metastatic Sarcoma
- Trial name
- NCT05711615
- Testing
- Biopsy Procedure, Biospecimen Collection, Computed Tomography
- Where
- 16 sites in United States
- Volunteers
- 30 people
- Sponsor
- National Cancer Institute (NCI)
Adult Patients With Unresectable Locally Advanced or Metastatic, Relapsed/Refractory Dedifferentiated Liposarcoma
Efficacy and Safety of Plitidepsin in Patients With Advanced Unresectable or Metastatic, Relapsed/Refractory, Dedifferentiated Liposarcoma (DLPS): an Exploratory Phase II Multicenter Trial
Liposarcomas are soft tissue sarcomas most frequent. We distinguish three subtypes on the basis of their histological and cytogenetic characteristics: well-differentiated liposarcoma / dedifferentiated, myxoid liposarcoma and /…
- Trial name
- APLIPO (NCT01876043)
- Testing
- plitidepsin
- Where
- 6 sites in France
- Volunteers
- 24 people
- Sponsor
- Institut Bergonié